Clinical Trial Update: Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas [Phase 3]

View source ↗

Summary

Phase 3 trial comparing FFX to CPI-613 with mFFX in metastatic pancreatic adenocarcinoma has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma
• Pancreatic Cancer

Drugs mentioned

• CPI-613 (devimistat)
• FFX
• mFFX

Snippet

Sponsor: Cornerstone Pharmaceuticals | Conditions: Pancreatic Cancer Metastatic | Phase 3 | Status: COMPLETED | Results posted: 2023-01-03